StreetAlpha.app
Home › Stocks › INBX

Inhibrx Biosciences, Inc. (INBX)

Healthcare
$68.97
▼ −7.21%
LAST CLOSE · NOV 20

Inhibrx Biosciences develops cancer treatments built from engineered proteins, now in clinical trials. It last closed at $68.97 on Nov 20, down 7.21% on the day. The next earnings report for INBX is expected around Thu, Mar 18, 2027, after the close. For the quarter ended Sep 2026, INBX reported EPS of -$2.46 on revenue of $2.0M. Over its last 8 reports the stock moved an average of 5.9% the session after earnings. Over the last 12 months INBX insiders bought $6.3M of stock on the open market and sold $279K, according to SEC Form 4 filings.

AI Auto Pilots
Is INBX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold INBX.

Key Stats

Last 12 months
Results
Revenue
$2.0M
+42.9% vs a year ago
Net income
−$141.7M
−7082.9% margin
EPS (diluted)
−$9.06
Free cash flow
−$132.7M
−6635.0% margin
Valuation
Market cap
$1.0B
14.8M shares
P/E
–
No P/E while losing money
Price to sales
509.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$199.5M
At Sep 30
Debt
$276.7M
At Sep 30
Shareholder equity
−$85.9M
Shares outstanding
14.8M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $1.8M$1.8MFY2023FY2024: $200K$200KFY2024FY2025: $1.3M$1.3MFY2025

From INBX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
Mar 18
Estimated date · After the close
Reported EPS
-$2.46
Quarter ended Sep 2026
Year ago EPS
-$2.28
Same quarter last year
Revenue
$2.0M
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$4.47Dec '24Mar 2025: -$2.80Mar '25Jun 2025: -$1.85Jun '25Sep 2025: -$2.28Sep '25Dec 2025: -$2.11Dec '25Mar 2026: -$2.15Mar '26Jun 2026: -$2.34Jun '26Sep 2026: -$2.46Sep '26Latest -$2.46
Revenue by quarter
Dec 2024: $100,000Dec '24Mar 2025: $0Mar '25Jun 2025: $1.3MJun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Jun 2026: $0Jun '26Sep 2026: $2.0MSep '26Latest $2.0M
How INBX moved after its last 8 reports
Average move the session after a report ±5.9%
Nov 13, 2026After the close−6.8%
Aug 13, 2026After the close−8.9%
May 14, 2026After the close−6.5%
Mar 19, 2026After the close−6.1%
Nov 13, 2025After the close+6.0%
Aug 13, 2025After the close+1.6%
May 14, 2025After the close+10.9%
Mar 17, 2025After the close+0.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on INBXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on INBX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on INBX

Technical Analysis

INBX · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 17% below its 20 day and 32% below its 50 day average. It is 34% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the Pivot S1 at $66.97, and the nearest resistance the Pivot at $70.78.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 10.2%/day
Key levels
$155.2952 week high+125.2%
$94.86100 day average+37.5%
$93.48Swing high (Nov 11)+35.5%
$92.47200 day average+34.1%
$91.1750 day average+32.2%
$80.8020 day average+17.2%
$72.79Pivot R1+5.5%
$70.78Pivot+2.6%
$68.97Last close
$66.97Pivot S1−2.9%
$66.80Swing low (Oct 30)−3.1%
$57.3052 week low−16.9%
Indicators
RSI (14)37.01Weak, oversold below 30Neutral
MACD-4.94Below its signal lineBearish
Stochastic11.8Near the bottom of its rangeOversold
ADX (14)17.2No clear trend
Williams %R-97.2Oversold below −80, overbought above −20Oversold
CCI (20)-104.5Oversold below −100, overbought above 100Oversold
Rate of change−18.4%Change over 10 sessionsBearish
ATR (14)$7.07Typical daily range, 10.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for INBX

What happened before

See how INBX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for INBXHow many large options trades hit INBX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

INBX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲95 buying vs 75 selling
  • ▲Held by funds +0.9 pts
  • ▲Funds holding +10
  • ▼Superinvestors: 1 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding173163+6.1%
In funds' top 1054+25.0%
Held by funds98.0%97.0%+0.9 pts
New / increased37 / 5850 / 55−9.5%
Reduced / sold out49 / 2639 / 21+25.0%
Put/call ratio0.280.05+409.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See INBX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

INBX Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$6.3M7 buys · 3 insiders
Sold$279K2 sales · 1 insider
Cluster buy: 3 insiders bought $5.5M between Sep 8 and Sep 28.
2026-09 bought $5.5M2026-09 sold $279K2026-10 bought $849KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 14Mark LappeCEOBuy10,040$84.56$849K
Sep 28Mark LappeCEOBuy10,000$99.88$999K
Sep 23Jon Faiz KayyemDirectorBuy5,000$100.00$500K
Sep 16Jon Faiz KayyemDirectorBuy5,000$100.00$500K
Sep 15Kimberly ManhardDirectorSale1,500$109.03$164K
Sep 9Kimberly ManhardDirectorSale1,000$115.47$115K
Every insider buy and sale for INBX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See INBX insider trades →

From SEC Form 4 filings by INBX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether INBX is in one of them and how their past INBX trades turned out.

INBX in the AI portfolios
Loading…

INBX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered INBX in an article yet. Here's the latest on the wider market.

INBX in the news

About Inhibrx Biosciences

Inhibrx Biosciences is a biopharmaceutical company based in La Jolla, California. It develops biologic drug candidates, which are medicines made from proteins, using its own protein engineering platforms. Its candidates are being tested in clinical trials for cancers, including sarcomas, colorectal cancer, lung cancer and head and neck cancer. The company aims to offer these treatments to patients with serious diseases, if they are approved.

Headquarters
La Jolla, CA